Brief: Roxadustat Granted Orphan Drug Designation For The Treatment Of Myelodysplastic Syndromes By The U.S. FDA
15/12/2025 12:11
Dec 15 (Reuters) - FibroGen Inc FGEN.O: ROXADUSTAT GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES BY THE U.S. FOOD AND DRUG ADMINISTRATION FIBROGEN INC - TO FILE PHASE 3 PROTOCOL IN Q4 2025 Source text: ID:nGNXKhy8D Further company coverage: FGEN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kyntra Bio
See all newsBrief: Kyntra Bio Appoints Andrew E. Singer, Mba To Its Board Of Directors
NASDAQ RESUMED AT 01:28 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:23 PM
Kyntra Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kyntra Bio swings to profit in Q2 on deconsolidation of subsidiary